GIST

	09/29/2009	New Tool Can Predict Risk of Cancer Recurrence After GIST Surgery - (DGNews)
	06/03/2009	Surgery Following Imatinib Treatment Appears to Improve Progression-Free Survival in Patients With GIST: Presented at ASCO - (DGDispatch)
	06/01/2009	Patients With Gastrointestinal Stromal Tumour Have Increased Risk of Second, Non-GIST Malignancies: Presented at ASCO - (DGDispatch)
	05/28/2009	NICE Recommends Sunitinib Malate as Second-Line Therapy for Advanced GIST - (DGNews)
	05/07/2009	Imatinib Approved in EU to Reduce Relapse Risk After GIST Surgery - (DGNews)
	01/17/2009	Sorafenib Shows Activity as Fourth-Line Therapy for Patients With GIST Tumours: Presented at ASCO-GI - (DGDispatch)
	01/14/2009	Surgery Provides Good Long-Term Outcomes for Patients With GI Cancers - (DGNews)
	12/22/2008	FDA Approves Imatinib Mesylate to Prevent Recurrence of GI Stromal Tumour - (DGNews)
	09/14/2008	Aprepitant Effective Antiemetic in Cancer Patients Regardless of Nausea Risk Factors: Presented at ESMO - (DGDispatch)
	07/31/2008	FDA Clears the Pathwork Tissue of Origin Test - (DGNews)
	06/17/2008	Researchers Evaluate the Role of Chemotherapy at the End of Life - (DGNews)
	04/22/2008	Sunitinib Approved in Japan for GIST and Renal Cell Carcinoma - (DGNews)
	02/11/2008	Sunitinib Effective in Advanced Gastrointestinal Stromal Tumours After Imatinib Failure: Presented at ICACT - (DGDispatch)
	01/27/2008	Proper Blood Levels of Imatinib Correlate With Better Clinical Response Against GISTs: Presented at ASCO-GI - (DGDispatch)
	01/27/2008	Patients Receiving Adjuvant Imatinib for GISTs Show 97% Survival at 3 Years: Presented at ASCO-GI - (DGDispatch)
	01/27/2008	Investigational Motesanib Provides Clinical Benefit in Phase 2 Trial: Presented at ASCO-GI - (DGDispatch)
	01/25/2008	Worldwide Study Shows No Differences in Sunitinib Effectiveness Outside of Clinical Trial: Presented at ASCO-GI - (DGDispatch)
	12/13/2007	Patients Given Sunitinib Need Close Monitoring for Cardiac Problems - (DGNews)
	06/11/2007	No Time Is a Good Time to Stop Imatinib Treatment for Patients With Advanced Gastrointestinal Stromal Tumours (GIST): Presented at ASCO - (DGDispatch)
	06/06/2007	More Than 90% of Gastrointestinal Stromal Tumour Patients Survive 2 Years With Imatinib After Surgery: Presented at ASCO - (DGDispatch)
	04/13/2007	Gleevec Decreases Recurrence for Patients With Primary Gastrointestinal Stromal Tumor - (DGNews)
	01/24/2007	Patients With Large GIST Respond Well to Imatinib Treatment: Presented at ASCO-GI - (DGDispatch)
	12/01/2006	KIT and PDGFRA Mutation Have Prognostication Value in Gastrointestinal Stromal Tumours: Presented at ESSO - (DGDispatch)
	10/02/2006	Health Canada Endorsed Important Safety Information on Gleevec (Imatinib Mesylate) - (DGNews)
	09/30/2006	Sunitinib Malate (Sutent) Safe and Effective for Gastrointestinal Stromal Tumors After Imatinib Fails: Presented at ESMO - (DGDispatch)
	09/15/2006	Single Genetic Assay Could Help Physicians Decide When to Switch Patients from Imatinib to Sunitinib - (DGNews)
	06/04/2006	Phase 3 Trial Update Shows Sunitinib Effective in Imatinib-Resistant GIST: Presented at ASCO - (DGDispatch)
	05/15/2006	Altered bone and mineral metabolism in patients receiving imatinib mesylate (N Engl J Med)
	05/15/2006	New Study Shows Initial Treatment With 800 mg/day Imatinib Mesylate Significantly Improved Progression-Free Survival in Group of High-Risk Patients With Rare Form of Gastrointestinal Cancer - (DGNews)
	04/28/2006	Pfizer's Sutent Receives Positive Opinion in the European Union For Two Difficult-To-Treat Advanced Cancers - (DGNews)